Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Endometrial Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Endometrial Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Sarcomas: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Sarcomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Sarcomas

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Bladder Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Bladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Bladder Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Melanoma: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Melanoma

Data Insights

Datopotamab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Triple-Negative Breast Cancer (TNBC)

Data Insights

Valemetostat by Daiichi Sankyo for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Valemetostat is under clinical development by Daiichi Sankyo and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Small-Cell Lung Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Small-Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Small-Cell Lung Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Triple-Negative Breast Cancer (TNBC)

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Metastatic Breast Cancer

Data Insights

Datopotamab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Triple-Negative Breast Cancer (TNBC)

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Datopotamab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Datopotamab deruxtecan by Daiichi Sankyo for Non-Small Cell Lung Cancer: Likelihood of Approval

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Non-Small Cell Lung Cancer

Data Insights

Trastuzumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval

Trastuzumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Metastatic Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Deruxtecan in Metastatic Breast Cancer

Data Insights

Esaxerenone by Daiichi Sankyo for Diabetic Hypertension: Likelihood of Approval

Esaxerenone is under clinical development by Daiichi Sankyo and currently in Phase II for Diabetic Hypertension. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Esaxerenone in Diabetic Hypertension

Data Insights

Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Datopotamab deruxtecan?

Datopotamab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Pre-Registration program in Non-Small Cell Lung...

Net Present Value Model: Daiichi Sankyo Co Ltd's Datopotamab deruxtecan